Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:NVO News 10 December 2025 - 5 February 2026

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
······
Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk warns 2026 sales could fall — and the Wegovy pill isn’t saving the mood yet

Novo Nordisk forecast 2026 adjusted sales and operating profit will fall 5%–13% at constant exchange rates, citing pricing pressure and competition. U.S.-listed shares dropped about 12% after the outlook. The company reported 2025 sales up 10% to 309.1 billion Danish crowns and operating profit up 6%. Early U.S. uptake of its Wegovy pill was noted, but patent expiries and lower realized prices remain concerns.
3 February 2026
····
Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

Novo Nordisk Class B stock heads into Monday with Wegovy pill scripts and Victoza lawsuit in focus

COPENHAGEN, Jan 24, 2026, 20:49 (CET) — Market closed Novo Nordisk A/S Class B shares (NOVOb.CO) closed higher on Friday in Copenhagen and head into the new week on that note, boosted by early signs of strong demand for its Wegovy weight-loss drug. Much of Novo’s profit hinges on its obesity-drug franchise, making the stock a stand-in for the durability of this trend. Prescription tallies offer one of the rare near-real-time glimpses investors have between earnings reports. Novo’s wager on pills is significant because it targets patients who steer clear of injections. It also taps into cash-pay demand, where patients
24 January 2026
·····
Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

Eli Lilly stock price: What to watch after Friday’s close as FDA review scrutiny and Novo’s pill data hit

New York, January 18, 2026, 10:06 EST — Market closed Eli Lilly shares ended Friday at $1,038.40, rising 0.5% after fluctuating between $1,019 and $1,049.83 during the session. With U.S. markets shut for the weekend, traders are left to digest regulatory and competitive developments ahead of Monday’s open. Why it matters now: Lilly’s next valuation boost hinges on weight loss, and investors are weighing two fresh signals — the speed of the U.S. drug regulator’s action, and whether pills can expand demand beyond injections. The setup is more delicate than it appears. Speeding up the timeline for a new oral
18 January 2026
······
Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

Eli Lilly stock edges up as $1 billion Nvidia AI lab plan hits JPM spotlight

New York, Jan 12, 2026, 10:58 EST — Regular session Eli Lilly’s stock climbed in early trading Monday following the announcement that the drugmaker and Nvidia plan to invest roughly $1 billion over five years in a joint research lab focused on accelerating drug discovery. The news comes as executives and investors gather at the J.P. Morgan Healthcare Conference in San Francisco, where buzz around drug pipelines can quickly shift valuations in a sector still relying on a handful of blockbuster drugs. AI is increasingly woven into the narrative, particularly for firms eager to prove they can go beyond their
12 January 2026
·······
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon.com (AMZN.O) shares rose 0.4% in after-hours trading on Friday after Amazon Pharmacy said it has begun offering Novo Nordisk’s (NOVOb.CO) Wegovy weight-loss pill via insurance plans as well as a cash-pay option. Customers who qualify and have commercial insurance could pay $25 for a one-month supply, while cash-pay begins at $149; the U.S. FDA approved the pill in December, Amazon said. AMZN last traded at $247.33, after ranging from $242.31 to $247.71 during the session. Novo has said the pill will also be available through CVS and Costco and through telehealth providers including Ro, LifeMD, WeightWatchers and GoodRx. (Reuters)
9 January 2026
······
Novo Nordisk stock slips premarket as China court backs key semaglutide patent

Novo Nordisk stock slips premarket as China court backs key semaglutide patent

NEW YORK, January 2, 2026, 05:42 ET — Premarket Novo Nordisk A/S shares edged lower in premarket trading on Friday after the Danish drugmaker said China’s Supreme People’s Court upheld a key patent covering semaglutide, the active ingredient in its blockbuster obesity and diabetes drugs. U.S.-listed American depositary receipts (ADRs) — certificates that represent foreign shares — were down about 0.7% at $50.88. The ruling matters because semaglutide underpins Wegovy for obesity and Ozempic and Rybelsus for type 2 diabetes, products that have driven Novo’s growth and investor attention. Patent protection on the molecule can help slow copycat competition in
2 January 2026
···
Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026

December 25, 2025 — U.S. markets are closed for Christmas, but healthcare stocks are ending the year with a burst of sector-defining catalysts: a landmark oral GLP‑1 approval for weight loss, multiple FDA green lights that moved biotech names sharply, and a renewed M&A drumbeat as big pharma and rare-disease specialists shop for growth. Below is a detailed, news-driven roundup of the most important healthcare stock headlines, forecasts, and analyst themes investors are digesting as of Dec. 25, 2025—and what they could mean for pharma stocks, biotech stocks, medtech stocks, and health insurance stocks in early 2026. Why healthcare stocks
25 December 2025
····
Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk (NVO) Stock Today: Worst Year on Record, Fresh Downgrades – and a New 2026 Forecast (11 December 2025)

Novo Nordisk A/S – the Danish maker of Ozempic and Wegovy – is having the kind of year investors usually wake up from, not live through. On 11 December 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) trade around $49 per share, after a bounce of roughly 5–6% in recent sessions. Copenhagen-listed B‑shares sit near 316 DKK, yet they remain close to 50% lower than where they started 2025, putting the stock on track for its worst year on record.MarketBeat+2MarketScreener+2 A new wave of research notes and news out today sharpen the picture: 2026 is now expected to be a year
11 December 2025
······
Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk A/S (NVO) Stock Today: Akero Deal, GLP‑1 Competition and Analyst Downgrades – What 10 December 2025 Means for Investors

Novo Nordisk stock is having a very noisy December 10, 2025. American depositary shares of Novo Nordisk A/S (ticker NVO) recently traded around $48 in New York, up roughly 3–4% intraday, with the session range hovering between about $47 and $48.3. That rebound comes after months of brutal underperformance and a barrage of fresh news: an M&A deal closing, obesity pipeline updates, an important downgrade from Argus, and increasingly loud questions about whether the GLP‑1 champion can hold its crown. This is exactly the kind of setup that confuses the daylights out of investors: bullish long‑term story, ugly short‑term chart,
10 December 2025
·····

Stock Market Today

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

7 February 2026
Carvana shares rose 5.21% Friday to $403.67, rebounding after recent volatility sparked by a short-seller report from Gotham City Research. The company denied allegations of overstated earnings and undisclosed ties to DriveTime. Carvana will report Q4 and full-year 2025 results after markets close on Feb. 18. The January U.S. CPI report is scheduled for Feb. 13.
Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

7 February 2026
Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
Go toTop